Indberetningspligtige transaktioner med Danske Andelskassers Bank A/S aktier
Selskabsmeddelelse nr. 05/2023 | 27. februar 2023
Danske Andelskassers Bank A/S indberetter hermed på vegne af bankens indberetningspligtige transaktioner med Danske Andelskassers Bank A/S aktier i henhold til Markedsmisbrugsforordningens artikel 19.
For yderligere detaljer henvises til vedhæftet skema hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til dem skal indberettes og offentliggøres.
Med venlig hilsen
Danske Andelskassers Bank A/S
Jan Pedersen
Adm. direktør
Kontaktinformation
Henvendelse vedrørende denne meddelelse kan ske til Direktionsassistent Mia Winkler Møller på telefon 29 68 35 56 eller mail mwm@andelskassen.dk
Vedhæftede filer
2023-02-27 Morten Gylling Andersen
Vedhæftede filer
- 05-2023 Selskabsmeddelelse- indberetning af ledende medarbejdere
- 2023-02-27 Skema Morten Gylling Andersen
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Sbanken ASA: Tap Issue ISIN NO001108758727.3.2023 15:19:31 CEST | Press release
Tap Issue Sbanken ASA 21/25 FRN C, ISIN NO0011087587 amount NOK 800.000.000,-. New outstanding amount NOK 3.500.000.000,- This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Sbanken ASA: Utvidelse av ISIN NO001108758727.3.2023 15:19:31 CEST | Pressemelding
Utvidelse av Sbanken ASA 21/25 FRN C, ISIN NO0011087587 beløp NOK 800.000.000,- Nytt utestående volum NOK 3.500.000.000,- Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast27.3.2023 15:05:00 CEST | Press release
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference C
Transactions in connection with share buy-back program27.3.2023 15:00:41 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 27, 2023 –Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 31, 2023, and comprises up to 220,000 shares. The following transactions were executed under the program from March 20, 2023, to March 24, 2023: No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement167,000427,631,620March 20, 20236,0002,504.2415,025,440March 21, 20235,000 2,541.7712,708,850March 22,20235,0002,541.4412,707,200March 23, 20237,0002,529.9917,709,930March 24, 20237,0002,564.9117,954,370Total30,00076,105,790Accumulated under the program197,000503,737,410 Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 740,416 shares as treasury shares, corresponding to 1.12% of the to
Philips Virtual Care Management offers a comprehensive approach to telehealth for patients, providers and payers27.3.2023 15:00:00 CEST | Press release
March 27, 2023 New solution demonstrates proven results in improving patient engagement, health outcomes, and lowering cost of care while enabling workflow efficiencies Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the debut of Philips Virtual Care Management, a comprehensive portfolio of flexible solutions and services to help health systems, providers, payers and employer groups more meaningfully motivate and deeply connect with patients from virtually anywhere. Philips Virtual Care Management can help reduce pressure on hospital staff by decreasing emergency department visits, as well as reducing the cost of care through better management of chronic disease [1][2]. Every year, chronic condition management represents 90% of healthcare expenditures in the USA [3]. Philips Virtual Care Management’s condition-specific protocols now include diabetes, hypertension, heart disease, chronic kidney disease, chronic obst